TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) Short term Debt (2023 - 2026)

Updated

TScan Therapeutics' Short term Debt came in at $15.7 million for Q3 2026, up 34.1% from the prior quarter.

Analysis

TScan Therapeutics (TCRX) Short term Debt (2023 - 2026) Analysis & Trends

At the end of FY2023, TScan Therapeutics' Short term Debt was $3.35 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn
9 Gsk 193.54 Bn 176.38 Bn -
10 TScan Therapeutics 18.87 Mn -434.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 15.70 Mn
Jun 30, 2026 11.71 Mn
Jun 30, 2024 10.34 Mn
Mar 31, 2024 6.80 Mn
Dec 31, 2023 3.35 Mn
Sep 30, 2023 1.11 Mn
API Access

TScan Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=TCRX&period=max&api_key=YOUR_API_KEY